ArticleBMC health services research2025
"What is it like to live with a CGM?": A qualitative study on type 1 diabetes patients' experiences.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of continuous glucose monitoring (CGM) is increasing in people with type 1 diabetes mellitus (T1DM) due to its convenience and usefulness for glucose management. PURPOSE: This qualitative study explores the experiences and challenges of patients with T1DM regarding their CGM use.
methodsTwenty-nine participants were recruited from a hospital and an online community between May 26 and October 5, 2022. Individual in-depth interviews were conducted, audio-recorded, and subsequently transcribed verbatim. Data were analyzed using Braun and Clarke's six-phase framework for thematic analysis.
resultsThe participants' ages ranged from 19 to 64 years, and the duration of CGM use varied from 2 to 84 months. The qualitative results revealed three themes: typical diabetes care, tied to CGM for life, and conditions for better use. The immediate monitoring capability of CGM was highlighted as a key advantage, liberating individuals from the fear of hypoglycemia and enhancing their overall quality of life. However, the participants also encountered inevitable inconveniences and shared common concerns regarding the accuracy of CGM and the financial burden associated with CGM costs.
conclusionsHealthcare providers and policymakers must address the concerns of patients with T1DM and implement educational activities to bridge the gap between self-monitoring of blood glucose (SMBG) and CGM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.